Phase 2 N=55 A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects
Influenza
Primary: Number of Participants With Solicited Injection Site and Systemic Adverse Events — 1; 2; 1; 3 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=955 Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings
Psoriasis
Primary: Duration of Drug-Free Interval Prior to Treatment Cycle 2 — 12.6 weeks
Phase 2 N=22 Doxazosin for Psychostimulant Dependence
Methamphetamine or Cocaine Dependence
Primary: Change in Psychostimulant-positive Urines Over Time — .6; .41; .79; .25 proportion of psychostimulant-pos urines — p=0.05
N/A N=12 FFA Hypertension and Inflammation in Lean and Obese Subjects
Diabetes · Hypertension · Obesity
Primary: Change in Flow-mediated Dilation From Baseline to 4 Hours — 0.16; -3.2; -0.9; -2.4 percent change in diameter
Phase 4 N=10 Tolvaptan for Ascites in Cirrhotic Patients
Ascites · Cirrhosis
Primary: Number of Participants With Worsening Ascites (Increase in Number of Paracentesis Procedures to Remove 2 Liters of Ascites Fluid) — 0 participants
Phase 1 N=24 Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets
Healthy
Primary: AUC0-∞ for Empagliflozin — 2780; 2870; 1110; 1070 nmol*h/L — p=0.0000
N/A N=24 Clinical Evaluation Of A New Two-Component Self-Etch Universal Adhesive
Composite Restorations · Tooth Lesions
Primary: Retention — 100; 100; 100; 97 percentage of restorations
Phase 2 N=14 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Kaposi´s Sarcoma
Primary: Number of Participants With Complete Response — 1; 3 participants
Phase 1 N=48 Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Empagliflozin — 2810; 2580; 2760; 2570 nmol*h/L…
Phase 2 N=25 Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Overall Response Rate of GTI-2040 Combined With HiDAC in Refractory or Relapsed AML — 3; 4 participants
Phase 2 N=47 Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Sarcoma · Gastrointestinal Stromal Tumors
Primary: 2-year Relapse Free Survival Rate — 93.6 percentage of participants
Phase 2 N=66 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
Adenocarcinoma of the Rectum · Mucinous Adenocarcinoma of the Colon · Recurrent Colon Cancer
Primary: Severe Adverse Event (SAE) Rate — 2; 2 participants
Phase 3 N=60 Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome
Fatigue Syndrome, Chronic
Primary: Change From Baseline in Multidimensional Fatigue Inventory (MFI)--General Fatigue Subscale Score — -3.3; -1.8 units on a scale — p=0.23
Phase 3 N=93 Sphenopalatine Nerve Block for Headache Tx360
Headache · Migraine
Primary: Number of Participants Who Reported a 50% or Greater Reduction in Pain at 15 Minutes as Measured on the 100mm Visual Analog Scale — 48.8; 41.3 percentage of participants
Phase 2 N=25 Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
Primary: Overall Objective Response Rate During Treatment Cycle 1 — 57.1; 100.0; 30.8 percentage of participants